Attention: Clinical Laboratories
Please share this announcement with:
- Medical Director, Laboratory Services
- Administrative Director and Managers, Laboratory Services
On June 18, 2020, the CDC issued an official health advisory regarding the detection of Ciprofloxacin-resistant, β-lactamase-producing Neisseria meningitidis
- Neisseria meningitidis isolates in the United States have been largely susceptible to the antibiotics recommended for treatment and prophylaxis. However, 11 meningococcal disease cases reported in the United States during 2019–2020 had isolates that contained a blaROB-1 β-lactamase gene associated with penicillin resistance, as well as mutations associated with ciprofloxacin resistance.
- Laboratories should be aware that CDC recommends that healthcare providers use antimicrobial susceptibility testing (AST) to determine susceptibility of all meningococcal isolates to penicillin before changing from empirical treatment with cefotaxime or ceftriaxone to penicillin or ampicillin.
Read the entire advisory here.
Questions? Reach out to firstname.lastname@example.org.